Shares of Reckitt Benckiser Group plc (OTCMKTS:RBGLY – Get Rating) have been given an average recommendation of “Hold” by the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $8,650.00.
Several equities research analysts have issued reports on RBGLY shares. Jefferies Financial Group lowered Reckitt Benckiser Group from a “hold” rating to an “underperform” rating in a research note on Wednesday, March 23rd. Royal Bank of Canada raised Reckitt Benckiser Group from a “sector perform” rating to an “outperform” rating in a research note on Wednesday, May 18th. Exane BNP Paribas raised Reckitt Benckiser Group from an “underperform” rating to a “neutral” rating in a research note on Monday, March 14th. Barclays boosted their target price on Reckitt Benckiser Group from GBX 9,100 ($110.45) to GBX 9,300 ($112.88) in a research note on Tuesday, May 3rd. Finally, Sanford C. Bernstein lowered Reckitt Benckiser Group from a “market perform” rating to an “underperform” rating in a research note on Monday, March 14th.
Shares of RBGLY stock opened at $14.90 on Friday. The company has a quick ratio of 0.44, a current ratio of 0.62 and a debt-to-equity ratio of 0.95. The business has a 50-day moving average price of $15.74 and a two-hundred day moving average price of $16.22. Reckitt Benckiser Group has a 12-month low of $14.40 and a 12-month high of $18.78.
About Reckitt Benckiser Group (Get Rating)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.
Further Reading
- Get a free copy of the StockNews.com research report on Reckitt Benckiser Group (RBGLY)
- Dividend Stocks and Your Roth IRA
- The Analysts Upgrade… Retail Stocks?
- The Q2 Earnings Season Could Be A Bloodbath
- The Institutions Turn The Tide For Jabil
- Commercial Metals Company Is Ready To Rebound
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.